Search research articles
Contact Us
Filters
Showing results (31-40 of 102) with videos related to
Page
of 11
Sort By:
Nature Communications
|
January 22, 2021
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, et al.
Cancer Research
|
April 3, 2003
ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas
Qun Wang, George Hii, Suzanne Shusterman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2007
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study
Susan R Rheingold, Michael D Hogarty, Susan M Blaney, et al.
Cancer Letters
|
December 6, 2014
TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma
Abdelkader Selmi, Maud de Saint-Jean, Anne-Catherine Jallas, et al.
Pediatric Blood & Cancer
|
March 21, 2009
Influence of neuroblastoma stage on serum-based detection of MYCN amplification
Valerie Combaret, Michael D Hogarty, Wendy B London, et al.
Cancer Research
|
May 17, 2012
Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma
Kelly C Goldsmith, Michelle Gross, Susan Peirce, et al.
Oncotarget
|
June 29, 2016
A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma
Francesco Maria Calabrese, Rosanna Clima, Piero Pignataro, et al.
Pediatric Blood & Cancer
|
February 10, 2021
BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers
Payal Jain, Lea F Surrey, Joshua Straka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification
Hannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.
Oncogene
|
April 15, 2005
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
Peter S White, Patricia M Thompson, Takahiro Gotoh, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 102) with videos related to
Sort By:
Page
of 11
Nature Communications
|
January 22, 2021
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
Babak Moghimi, Sakunthala Muthugounder, Samy Jambon, et al.
Cancer Research
|
April 3, 2003
ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas
Qun Wang, George Hii, Suzanne Shusterman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2007
Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study
Susan R Rheingold, Michael D Hogarty, Susan M Blaney, et al.
Cancer Letters
|
December 6, 2014
TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma
Abdelkader Selmi, Maud de Saint-Jean, Anne-Catherine Jallas, et al.
Pediatric Blood & Cancer
|
March 21, 2009
Influence of neuroblastoma stage on serum-based detection of MYCN amplification
Valerie Combaret, Michael D Hogarty, Wendy B London, et al.
Cancer Research
|
May 17, 2012
Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma
Kelly C Goldsmith, Michelle Gross, Susan Peirce, et al.
Oncotarget
|
June 29, 2016
A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma
Francesco Maria Calabrese, Rosanna Clima, Piero Pignataro, et al.
Pediatric Blood & Cancer
|
February 10, 2021
BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers
Payal Jain, Lea F Surrey, Joshua Straka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 25, 2023
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification
Hannah G Bender, Meredith S Irwin, Michael D Hogarty, et al.
Oncogene
|
April 15, 2005
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
Peter S White, Patricia M Thompson, Takahiro Gotoh, et al.
Page
of 11